ARTICLE | Clinical News
Microplasmin: Phase II started
December 21, 2009 8:00 AM UTC
Thrombogenics began the double-blind, sham-controlled, European Phase II MIVI 5 trial to evaluate 125 µg intravitreal microplasmin in about 100 patients with wet age-related macular degeneration. ...